230 related articles for article (PubMed ID: 14716146)
1. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Vanhoefer U
Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
[TBL] [Abstract][Full Text] [Related]
2. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
3. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
4. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
Jackson C; Cunningham D
Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
6. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
7. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
8. The role of targeted therapy in the treatment of colorectal cancer.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
10. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
Smith D; Bosacki C; Merrouche Y
Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
[TBL] [Abstract][Full Text] [Related]
11. [Which role do new therapeutic options play in palliative care of colorectal cancer?].
Verbeek W; Graeven U
Internist (Berl); 2005 Dec; 46(12):1339-46. PubMed ID: 16228155
[TBL] [Abstract][Full Text] [Related]
12. [Biotherapy in colorectal cancer].
Des Guetz G
J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
Vincenzi B; Santini D; Russo A; Silletta M; Gavasci M; Battistoni F; Di Cuonzo G; Rocci L; Gebbia N; Tonini G
Ann Oncol; 2006 May; 17(5):835-41. PubMed ID: 16507564
[TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
Zhang W; Azuma M; Lurje G; Gordon MA; Yang D; Pohl A; Ning Y; Bohanes P; Gerger A; Winder T; Hollywood E; Danenberg KD; Saltz L; Lenz HJ
Anticancer Res; 2010 Oct; 30(10):4209-17. PubMed ID: 21036743
[TBL] [Abstract][Full Text] [Related]
15. A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Taniguchi H; Komori A; Narita Y; Kadowaki S; Ura T; Andoh M; Yatabe Y; Komori K; Kimura K; Kinoshita T; Muro K
Jpn J Clin Oncol; 2016 Mar; 46(3):228-33. PubMed ID: 26759349
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
17. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study.
Feliu Batlle J; Cuadrado E; Castro J; Caldés T; Belda C; Sastre J; Barriuso J; Martínez Marín V; Díaz-Rubio E; González-Barón M
Chemotherapy; 2011; 57(2):138-44. PubMed ID: 21447947
[TBL] [Abstract][Full Text] [Related]
19. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Mahtani RL; Macdonald JS
Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Heinemann V; Hoff PM
Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
